Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on norucholic acid in primary sclerosing cholangitis
May 7, 2025
Freiburg, May 7th, 2025 Study results demonstrate superiority of norucholic acid (NCA) over placebo in